<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article  article-type="reviewer-report"        dtd-version="1.4">
            <front>

                <journal-meta>
                                    <journal-id></journal-id>
            <journal-title-group>
                                                                                    <journal-title>Ankara Üniversitesi Tıp Fakültesi Mecmuası</journal-title>
            </journal-title-group>
                            <issn pub-type="ppub">0365-8104</issn>
                                        <issn pub-type="epub">1307-5608</issn>
                                                                                            <publisher>
                    <publisher-name>Ankara University</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id/>
                                                                <article-categories>
                                            <subj-group  xml:lang="en">
                                                            <subject>Medical Pharmacology</subject>
                                                    </subj-group>
                                            <subj-group  xml:lang="tr">
                                                            <subject>Tıbbi Farmakoloji</subject>
                                                    </subj-group>
                                    </article-categories>
                                                                                                                                                        <title-group>
                                                                                                                        <trans-title-group xml:lang="tr">
                                    <trans-title>P2X7 Reseptörü Aracılı Hücre Membran Geçirgenlik Artıșı</trans-title>
                                </trans-title-group>
                                                                                                                                                                                                <article-title>P2X7 Reseptörü Aracılı Hücre Membran Geçirgenlik Artıșı  P2X7</article-title>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0002-3757-8709</contrib-id>
                                                                <name>
                                    <surname>Cankurtaran Sayar</surname>
                                    <given-names>Şerife</given-names>
                                </name>
                                                                    <aff>ANKARA ÜNİVERSİTESİ, TIP FAKÜLTESİ, TEMEL TIP BİLİMLERİ BÖLÜMÜ, BİYOFİZİK ANABİLİM DALI</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0001-6807-4741</contrib-id>
                                                                <name>
                                    <surname>Sayar</surname>
                                    <given-names>Kemal</given-names>
                                </name>
                                                                    <aff>ANKARA ÜNİVERSİTESİ, ANKARA TIP FAKÜLTESİ</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20181016">
                    <day>10</day>
                    <month>16</month>
                    <year>2018</year>
                </pub-date>
                                        <volume>71</volume>
                                        <issue>1</issue>
                                        <fpage>31</fpage>
                                        <lpage>34</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20161023">
                        <day>10</day>
                        <month>23</month>
                        <year>2016</year>
                    </date>
                                                    <date date-type="accepted" iso-8601-date="20180222">
                        <day>02</day>
                        <month>22</month>
                        <year>2018</year>
                    </date>
                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 1947, Ankara Üniversitesi Tıp Fakültesi Mecmuası</copyright-statement>
                    <copyright-year>1947</copyright-year>
                    <copyright-holder>Ankara Üniversitesi Tıp Fakültesi Mecmuası</copyright-holder>
                </permissions>
            
                                                                                                <trans-abstract xml:lang="tr">
                            <p>Pürinerjik reseptörler P2X ve P2Y olmak üzere iki ana aileden olușmaktadır. P2Y reseptörleri G-proteini kenetli reseptörler (GPKR), P2X reseptörleri seçici olmayan katyon kanallarıdır. P2X reseptörlerinin 7 üyesinden biri olan P2X7 reseptörü immün hücreler bașta olmak üzere birçok tip hücrede bulunmaktadır. IL-1β salınımı, kaspaz aktivasyonu gibi hücre içinde birçok sinyal yolağını aktive etmekle beraber, diğer üyelerden farklı olarak membranda büyük bir geçirgenlik aktive etmektedir. Membran geçirgenliğini incelemek için spektroskopik ve elektrofizyolojik yöntemler kullanılmaktadır. Büyük geçirgenliğin mekanizmasını açıklamak için çeșitli hipotezler öne sürülmektedir. Bunlardan biri P2X7 kanalının genișleyerek büyük moleküllere geçirgen hale geldiği, diğeri ise geçirgenliğin bașka bir protein aracılığıyla olduğudur. P2X7 reseptörü inflamasyon, ağrı, kanser ve Alzhzeimer gibi birçok hastalıkta rolü olduğu gösterilen bir reseptör olduğu için antagonistleri ve modülatörleri iyi birer ilaç hedefi olarak görülmektedir. Aktivasyon mekanizmasının aydınlatılması da birçok hastalığın tedavisi için önem tașımaktadır.</p></trans-abstract>
                                                                                                                                    <abstract><p>Purinergic receptors consist of two main families; P2X and P2Y. P2Y receptors are G protein coupled receptors (GPCR), whereas P2X receptors are non-selective cation channels. P2X7 receptors which is a member of P2X receptors, have been found myriad types of cells including immune cells. The activation of this receptor leads to IL-1β release and caspase activation as well as an increase in membranepermeability to big molecules. Spectroscopic and electrophysiologic methods have been used to investigate membrane permeability. Different hypotheses have been proposed as an explanation for big permeability. One of them proposes that P2X7 channel itself dilates and becomes permeable to big molecules, whereas the other proposes participation of another channels to big permeability. Since it has been demonstrated that P2X7 receptor has a role in many disease processes including inflamation, pain, cancer and Alzheimer’s disease, its antagonists and modulators have been regarded as a good drug target. The uncovering of its activation mechanism is important for treatment of many diseases.</p></abstract>
                                                            
            
                                                                                        <kwd-group>
                                                    <kwd>P2X7 Receptor</kwd>
                                                    <kwd>  Membrane Permeability</kwd>
                                                    <kwd>  YoPro-1</kwd>
                                                    <kwd>  Lucifer Yellow</kwd>
                                            </kwd-group>
                            
                                                <kwd-group xml:lang="tr">
                                                    <kwd>P2X7 Reseptörü</kwd>
                                                    <kwd>  Membran Geçirgenliği</kwd>
                                                    <kwd>  YoPro-1</kwd>
                                                    <kwd>  Lusifer Yellow</kwd>
                                            </kwd-group>
                                                                                                                                        </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">1. Burnstock G, Campbell G, Satchell D, et al. Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut. Br J Pharmacol. 1970; 40:668–688.</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">2. Schwiebert EM, Zsembery A, Geibely JP. Cellular Mechanisms and Physiology of Nucleotide and Nucleoside Release from Cells: Current Knowledge, Novel Assays to Detect Purinergic Agonists, and Future Directions. Current Topics in Membranes. 2003; Volume 54:31-58</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">3. Burnstock G. Introduction and perspective, historical note. Front Cell Neurosci. 2013;7:1-13</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">4. Ivar von Kügelgen. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Biotrend Reviews. 2008; 9:1-12</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">5. North RA ve Barnard EA. Nucleotide receptors. Curr Opin Neurobiol. 1997; Jun 110(3):415-32</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">6. Surprenant A ve North RA. Signaling at purinergic P2X receptors. Annu Rev Physiol. 2009; 71:333-59</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">7. Burnstock G. Purinergic signalling: from discovery to current developments. Exp Physiol. 2014; 99(1):16-34</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">8. Surprenant A, Rassendren F, Kawashima E et al. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science. 1996; 272: 735–738.</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">9. Bartlett R, Stokes L, Sluyter R. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Pharmacol Rev. 2014; 66(3):638-75.</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">10. Jacobson KA, Müller CE. Medicinal chemistry of adenosine, P2Y and P2X receptors. Neuropharmacology. 2016; May 104:31-49.</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">11. North RA. Molecular physiology of P2X receptors. Physiol Rev. 2002; 82: 1013–1067.</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">12. North RA, Surprenant A. pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol. 2000; 40:563-80. Review.</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">13. Coddou C, Yan Z, Obsil T, et al. Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev. 2011; 63(3):641-83.</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">14. Jarvis MF, Khakh BS. ATP-gated P2X cation- channels. Neuropharmacology. 2009; 56(1):208-15</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">15. Donnelly-Roberts D L, Namovic MT, Surber B, et al. [3H]A-804598 ([3H]2- cyano-1-[(1S)-1 phenylethyl]-3-quinolin-5- ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors. Neuropharmacology. 2009; 56(1):223-9.</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">16. Saul A, Hausmann R, Kless A, et al. Heteromeric assembly of P2X subunits. Front Cell Neurosci. 2013; 18:7:250</mixed-citation>
                    </ref>
                                    <ref id="ref17">
                        <label>17</label>
                        <mixed-citation publication-type="journal">17. Jıang, LH. Inhibition of P2X(7) receptors by divalent cations: old action and new insight. Eur Biophys J. 2009; 38(3):339-46</mixed-citation>
                    </ref>
                                    <ref id="ref18">
                        <label>18</label>
                        <mixed-citation publication-type="journal">18. Yan Z, Lı S, Lıang Z, et al.The P2X7 receptor channel pore dilates under physiological ion conditions. J Gen Physiol. 2008; 132(5):563-73.</mixed-citation>
                    </ref>
                                    <ref id="ref19">
                        <label>19</label>
                        <mixed-citation publication-type="journal">19. Virginio C, Church D, North RA, Surprenant A. Effects of divalent cations, protons and calmidazolium at the rat P2X7 receptor. Neuropharmacology. 1997; 36(9):1285-94.</mixed-citation>
                    </ref>
                                    <ref id="ref20">
                        <label>20</label>
                        <mixed-citation publication-type="journal">20. Virginio C, Mackenzie A, North RA, Surprenant A. Kinetics of cell lysis, dye uptake and permeability changes in cells expressing the rat P2X7 receptor. J Physiol 1999; 519: 335–346.</mixed-citation>
                    </ref>
                                    <ref id="ref21">
                        <label>21</label>
                        <mixed-citation publication-type="journal">21. Thomas H. Steinberg, Alan S. Newman, Joel A. Swanson, Samuel C. Silverstein. ATP4- Permeabilizes the plasma membrane of mouse macrophages to fluorescent dyes. The Journal of Biological Chemistry. 1987; 262(18):8884-8888.</mixed-citation>
                    </ref>
                                    <ref id="ref22">
                        <label>22</label>
                        <mixed-citation publication-type="journal">22. Schachter J, Motta AP, de Souza Zamorano A, et al. ATP-induced P2X7-associated uptake of large molecules involves distinct mechanisms for cations and anions in macrophages. J Cell Sci. 2008; 121: 3261-3270.</mixed-citation>
                    </ref>
                                    <ref id="ref23">
                        <label>23</label>
                        <mixed-citation publication-type="journal">23. Cankurtaran-Sayar S, Sayar K, Ugur M. P2X7 receptor activates multiple selective dye permeation pathways in RAW 264.7 and human embryonic kidney 293 cells. Mol Pharmacol. 2009; 76:1323-1332.</mixed-citation>
                    </ref>
                                    <ref id="ref24">
                        <label>24</label>
                        <mixed-citation publication-type="journal">24. Ferreira LGB, Reis RAM, Alves LA, et al. Intracellular Signaling Pathways Integrating the Pore Associated with P2X7R Receptor with Other Large Pores. Patch Clamp Technique. Intech; Chapter 2:37-54</mixed-citation>
                    </ref>
                                    <ref id="ref25">
                        <label>25</label>
                        <mixed-citation publication-type="journal">25. Nielsen MS, Axelsen LN, Sorgen PL, et al. Holstein-Rathlou NH Gap junctions. Compr Physiol. 2012; Jul2(3):1981-2035.</mixed-citation>
                    </ref>
                                    <ref id="ref26">
                        <label>26</label>
                        <mixed-citation publication-type="journal">26. Beyer EC, Steinberg TH. Evidence that the gap junction protein connexin-43 isthe ATP-induced pore of mouse macrophages. J Biol Chem. 1991; 266:7971-7974.</mixed-citation>
                    </ref>
                                    <ref id="ref27">
                        <label>27</label>
                        <mixed-citation publication-type="journal">27. Alves LA, Coutinho-Silva R, Persechini PM, et al. Are there functional gap junctions or junctional hemichannels in macrophages? Blood. 1996; 88: 328-334.</mixed-citation>
                    </ref>
                                    <ref id="ref28">
                        <label>28</label>
                        <mixed-citation publication-type="journal">28. Faria RX, Defarias FP, Alves LA. Are second messengers crucial for opening the pore associated with P2X7 receptor? Am J Physiol Cell Physiol. 2005; 288: C260-71.</mixed-citation>
                    </ref>
                                    <ref id="ref29">
                        <label>29</label>
                        <mixed-citation publication-type="journal">29. Dahl G, Keane RW. Pannexin: From discovery to bedside in 11±4 years? BrainResearch. 2012; 1487:150-9</mixed-citation>
                    </ref>
                                    <ref id="ref30">
                        <label>30</label>
                        <mixed-citation publication-type="journal">30. Pelegrin P, Surprenant A. Pannexin-1 mediates large pore formation and interleukin- 1b release by the ATP-gated P2X7 receptor. EMBO J. 2006; 25:5071–5082</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
